Discrepancies among Measures of Executive Functioning in a Subsample of Young Adult Survivors of Childhood Brain Tumor: Associations with Treatment Intensity.
Treatments for childhood brain tumors (BT) confer substantial risks to neurological development and contribute to neuropsychological deficits in young adulthood. Evidence suggests that individuals who experience more significant neurological insult may lack insight into their neurocognitive limitations. The present study compared survivor, mother, and performance-based estimates of executive functioning (EF), and their associations with treatment intensity history in a subsample of young adult survivors of childhood BTs.



Thirty-four survivors (52.9% female), aged 18 to 30 years (M=23.5; SD=3.4), 16.1 years post-diagnosis (SD=5.9), were administered self-report and performance-based EF measures. Mothers also rated survivor EF skills. Survivors were classified by treatment intensity history into Minimal, Average/Moderate, or Intensive/Most-Intensive groups. Discrepancies among survivor, mother, and performance-based EF estimates were compared.



Survivor-reported and performance-based measures were not correlated, although significant associations were found between mother-reported and performance measures. Survivors in the Intensive/Most-Intensive treatment group evidenced the greatest score discrepancies, reporting less executive dysfunction relative to mother-reported F(2,31)=7.81, p.05).



There may be a lack of agreement among survivor, mother, and performance-based estimates of EF skills in young adult survivors of childhood BT, and these discrepancies may be associated with treatment intensity history. Neuropsychologists should use a multi-method, multi-reporter approach to assessment of EF in this population. Providers also should be aware of these discrepancies as they may be a barrier to intervention efforts. (JINS, 2016, 22, 900-910).
1Division of Oncology,The Children's Hospital of Philadelphia,Philadelphia,Pennsylvania.
Mark D
MD
McCurdy
1Division of Oncology,The Children's Hospital of Philadelphia,Philadelphia,Pennsylvania.
Elise M
EM
Turner
1Division of Oncology,The Children's Hospital of Philadelphia,Philadelphia,Pennsylvania.
Lamia P
LP
Barakat
1Division of Oncology,The Children's Hospital of Philadelphia,Philadelphia,Pennsylvania.
Wendy L
WL
Hobbie
5University of Pennsylvania School of Nursing,University of Pennsylvania,Philadelphia,Pennsylvania.
Janet A
JA
Deatrick
1Division of Oncology,The Children's Hospital of Philadelphia,Philadelphia,Pennsylvania.
Iris
I
Paltin
1Division of Oncology,The Children's Hospital of Philadelphia,Philadelphia,Pennsylvania.
Michael J
MJ
Fisher
1Division of Oncology,The Children's Hospital of Philadelphia,Philadelphia,Pennsylvania.
Matthew C
MC
Hocking
D000293:Adolescent; D000328:Adult; D001932:Brain Neoplasms / Q000150:complications* / Q000628:therapy; D000073116:Cancer Survivors; D002648:Child; D060825:Cognitive Dysfunction / Q000175:diagnosis* / Q000209:etiology; D056344:Executive Function / Q000502:physiology*; D005260:Female; D006801:Humans; D008297:Male; D009035:Mothers; D009483:Neuropsychological Tests / Q000592:standards; D057566:Self Report / Q000592:standards; D055815:Young Adult
Anosognosia; Awareness; Cancer; Impaired insight; Late-effects; Pediatric